Answer
Naloxegol is not recommended with rifampin, a strong CYP3A4 inducer, because co-administration reduced naloxegol exposure (AUC) by 89% and peak concentration (Cmax) by 76% compared with naloxegol alone.
Sources for this answer
- Moventig 25mg film-coated tabletsGrunenthal Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 14Document updated
Sources checked